Competitor Analysis: PD-1 and PD-L1 Immune Checkpoint Inhibitors 2016

Publisher: La Merie Publishing
Pages: 53
Format: PDF and Online
Product Line:
Competitor Analysis
Product Line:
Target Pipeline
Product Code: LMCA0156
Release Date: October of 2016

400.00 €
Free of 19 % VAT (except in Germany and also in the European Union without valid intl. VAT no),
Delivery costs do not apply or are included.
You can also order this product via email or fax , please download the Order Form
Need more information?
Ask a question about this product

Competitor Analysis: PD-1 and PD-L1 Immune Checkpoint Inhibitors 2016 

This Competitive Intelligence report about PD-1 and PD-L1 Immune Checkpoint Inhibitors 2016 provides a competitor evaluation in the field of antibody, protein, peptide, viral and small molecules inhibitors of the immune checkpoints programmed cell death 1 (PD-1) receptor and ligand 1 (PD-L1) as of October 2016.

Purchase of the pdf report includes a 6-month online access to the data of the report and any updates since the publication date as well as the clinical and preclinical combination studies. Credentials to access the database will be sent by e-mail and allow online work with the project data to print or export an individual report. The pdf report lists the molecules targeting PD-1 and PD-L1 and the database additionally includes the numerous currently ongoing combination studies.

The report includes a compilation of currently active projects in research and development of PD-1 and PD-L1 immune checkpoint inhibitors. The report differentiates between specific and bispecific PD-1 receptor antagonists and PD-L1 inhibitors. Furthermore, the report includes non-antibody PD-1 and PD-L1 immune checkpoint inhibitorrs, including proteins, peptides, viruses and small molecules. In addition, the report lists company-specific R&D pipelines of PD-1 and PD-L1 Immune Checkpoint Inhibitors. Competitor projects are listed in a tabular format providing information on:

  • Drug Codes,
  • Target / Mechanism of Action,
  • Class of Compound,
  • Company,
  • Product Category,
  • Indication,
  • R&D Stage and
  • additional comments with a hyperlink leading to the source of information.

About Competitor Analysis Series:
The Competitor Analysis Series delivers NO-FRILLS, but concise information about the pipeline of R&D projects for targets, diseases, technologies and companies at low prices. The information is provided in a tabular format and fully referenced.

Competitor Analysis: PD-1 and PD-L1 Immune Checkpoint Inhibitors 2016 

Table of Contents

1) Programmed Cell Death 1 (PD-1) Receptor Antagonists
Specific Anti-PD-1 Antibodies
Bispecific Anti-PD-1 Antibodies
Non-Antibody PD-1 Receptor Antagonists

2) Programmed Cell Death 1 Receptor Ligand 1 (PD-L1) Inhibitors
Specific Anti-PD-L1 Antibodies
Bispecific Anti-PD-L1 Antibodies
Non-Antibody PD-L1 Inhibitors

3) Corporate PD-1 & PD-L1 Immune Checkpoint Inhibitor R&D Pipeline

The above shown price refers to a Single User License. Please contact us for prices of departmental, site or global product licenses.

This Report is NOT a downloadable item but will be delivered via email within 24 h (working days only).

La Merie Biologics

FREE Weekly News Bulletin

Sign Up

2017 Sales ofAntibodies & Proteins

New Product Alert

For La Merie Publishing

Sign Up